Company Encyclopedia
View More
name
ZeZentalis Pharma
ZNTL.US
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC.
1.946 T
ZNTL.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking274/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-49.18%E
    • Profit Margin-555.80%E
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-33.76%E
    • Net Profit YoY16.72%B
    • Total Assets YoY-27.38%E
    • Net Assets YoY-28.63%E
  • Cash ScoreD
    • Cash Flow Margin-17.99%D
    • OCF YoY-33.76%E
  • Operating ScoreE
    • Turnover0.07E
  • Debt ScoreA
    • Gearing Ratio22.73%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold

    Wall Street Zen upgraded Zentalis Pharmaceuticals (NASDAQ:ZNTL) from a "sell" to "hold" rating. Other analysts have mixed ratings, with one "strong buy," five "hold," and one "sell." The stock has a consensus "hold" rating and an average price target of $4.53. Zentalis focuses on developing cancer therapeutics and has several ongoing clinical trials. Hedge funds have recently adjusted their holdings in the company.

    Market Beat·
    US
    ZNTL
    +1.45%
    Market Beat·
    US
    ZNTL
    +1.45%

    Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)

    Oppenheimer analyst Matthew Biegler has maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL) with a price target of $9.00, while the stock closed at $1.32. The overall analyst consensus for Zentalis is a Moderate Buy, with an average price target of $10.00. Biegler has a -4.2% average return and a 38.97% success rate on his stock recommendations.

    Tip Ranks·
    US
    ZNTL
    +1.45%
    Tip Ranks·
    US
    ZNTL
    +1.45%

    Buy Rating for Zentalis Pharmaceuticals Driven by Promising Clinical Progress and Strategic Focus on PROC

    TD Cowen analyst Tyler Van Buren has maintained a Buy rating for Zentalis Pharmaceuticals (ZNTL) due to promising clinical progress and a strategic focus on PROC. The ongoing DENALI Part 2 study is expected to yield significant data by the end of 2026, positioning the company for potential accelerated approval. Previous trials have shown notable improvements over standard chemotherapy, with an objective response rate of 31-35%. H.C. Wainwright also reiterated a Buy rating with a $10.00 price target on October 27.

    Tip Ranks·
    US
    ZNTL
    +1.45%
    Tip Ranks·
    US
    ZNTL
    +1.45%

    Zentalis Pharmaceuticals Reports Q3 2025 Financial Results

    Zentalis Pharmaceuticals (ZNTL) reported its Q3 2025 financial results, showcasing progress in its DENALI Phase 2 trial for azenosertib, with topline data expected by late 2026. The company has $280.7 million in cash, supporting operations until late 2027, and has reduced R&D expenses. Analysts rate ZNTL stock as a Buy with a $10.00 price target, though Spark's AI Analyst considers it Neutral due to financial challenges and weak momentum. Zentalis focuses on developing azenosertib for aggressive cancers, despite facing significant risks.

    Tip Ranks·
    US
    ZNTL
    +1.45%
    Tip Ranks·
    US
    ZNTL
    +1.45%

    ZeZentalis Pharma | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ZNTL
    +1.45%
    LB filings·
    US
    ZNTL
    +1.45%
    © 2025 Longbridge｜Disclaimer